Caris Life Sciences, Inc. Common Stock Cash Flow Conversion Efficiency
Caris Life Sciences, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has a cash flow conversion efficiency ratio of 0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($61.35 Million) by net assets ($591.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Caris Life Sciences, Inc. Common Stock (2005–2025)
Cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. This chart illustrates how Caris Life Sciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CAI share price today for real-time trading data and today's change.
Caris Life Sciences, Inc. Common Stock Cash Flow Conversion Ratio Explained
Caris Life Sciences, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Caris Life Sciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see CAI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
StandardAero, Inc.
NYSE:SARO
|
-0.044x |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
0.025x |
|
DUFRY AG UNSP.ADR/010
F:D2JA
|
N/A |
|
Nemetschek AG O.N.
XETRA:NEM
|
0.028x |
|
Founder Securities Co Ltd
SHG:601901
|
-0.087x |
|
Corteva Inc
NYSE:CTVA
|
-0.018x |
|
Dundee Precious Metals Inc
TO:DPM
|
0.057x |
|
GAZTR.TECHNI.U.ADR1/5EO01
F:9TG0
|
N/A |
Annual Cash Flow Conversion Efficiency for Caris Life Sciences, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. Review CAI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $577.31 Million | $83.16 Million | 0.144x | +46.79% |
| 2024-12-31 | $-2.50 Billion | $-245.20 Million | 0.098x | -23.77% |
| 2023-12-31 | $-2.14 Billion | $-276.10 Million | 0.129x | -23.31% |
| 2022-12-31 | $-1.70 Billion | $-285.71 Million | 0.168x | -57.45% |
| 2020-12-31 | $702.24 Million | $277.02 Million | 0.394x | +7.66% |
| 2019-12-31 | $693.24 Million | $254.00 Million | 0.366x | +42.90% |
| 2018-12-31 | $701.13 Million | $179.77 Million | 0.256x | -6.84% |
| 2017-12-31 | $563.85 Million | $155.19 Million | 0.275x | -2.58% |
| 2016-12-31 | $457.50 Million | $129.26 Million | 0.283x | -11.57% |
| 2015-12-31 | $461.26 Million | $147.37 Million | 0.319x | +1.30% |
| 2014-12-31 | $442.90 Million | $139.69 Million | 0.315x | +5.43% |
| 2013-12-31 | $415.13 Million | $124.19 Million | 0.299x | -2.87% |
| 2012-12-31 | $346.85 Million | $106.83 Million | 0.308x | +6.25% |
| 2011-12-31 | $248.74 Million | $72.11 Million | 0.290x | +35.07% |
| 2010-12-31 | $197.67 Million | $42.42 Million | 0.215x | -10.04% |
| 2009-12-31 | $129.10 Million | $30.80 Million | 0.239x | -1.06% |
| 2008-12-31 | $113.79 Million | $27.44 Million | 0.241x | +11988.54% |
| 2007-12-31 | $131.15 Million | $-266.00K | -0.002x | -100.67% |
| 2006-12-31 | $27.75 Million | $8.38 Million | 0.302x | -66.15% |
| 2005-12-31 | $32.99 Million | $29.41 Million | 0.891x | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more